Provided by Tiger Trade Technology Pte. Ltd.

BlossomHill Therapeutics

18.30
-1.2600-6.44%
Pre-market: 18.300.00000.00%07:00 EDT
Volume:101.56K
Turnover:1.86M
Market Cap:560.78M
PE:-7.49
High:19.57
Open:19.57
Low:17.59
Close:19.56
52wk High:20.61
52wk Low:15.25
Shares:30.64M
Float Shares:9.38M
Volume Ratio:0.76
T/O Rate:1.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4440
EPS(LYR):-24.8342
ROE:--
ROA:--
PB:-3.69
PE(LYR):-0.74

Loading ...

Leerink Partners Initiates BlossomHill Therapeutics at Outperform, $36 Price Target

MT Newswires Live
·
60 mins ago

BlossomHill Therapeutics to Present Updated Phase 1/2 Solara Trial Data on BH-30643 in EGFR-Mutant NSCLC at WCLC 2026

Reuters
·
1 hour ago

BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer

GlobeNewswire
·
1 hour ago

BlossomHill Therapeutics Price Target Announced at $35.00/Share by HC Wainwright & Co.

Dow Jones
·
1 hour ago

BlossomHill Therapeutics initiated with an Outperform at LifeSci Capital

TIPRANKS
·
2 hours ago

BlossomHill Therapeutics initiated with a Buy at Guggenheim

TIPRANKS
·
2 hours ago

Blossomhill Therapeutics, Inc. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $35

THOMSON REUTERS
·
2 hours ago

BlossomHill Therapeutics initiated with an Overweight at JPMorgan

TIPRANKS
·
2 hours ago

U.S. Research Roundup-Autodesk, Hubspot, Oracle

Reuters
·
5 hours ago

Blossomhill Therapeutics Inc : JP Morgan Initiates Coverage with Overweight Rating; Target Price $28

THOMSON REUTERS
·
8 hours ago

Sector Update: Healthcare Stocks Flat to Higher Premarket Tuesday

MT Newswires Live
·
Aug 18

BlossomHill Says BH-30643 Gets FDA Fast Track Designation in Non-Small Cell Lung Cancer

MT Newswires Live
·
Aug 18

BlossomHill Therapeutics receives fast track designation for BH-30643 from FDA

TIPRANKS
·
Aug 18

Blossomhill Therapeutics Announces FDA Fast Track Designation for Bh-30643, a Macrocyclic Omni-Egfr™ Inhibitor for the Treatment of Advanced Egfr C797s-Positive Nsclc

THOMSON REUTERS
·
Aug 18

Major Insider Buying Spree Signals Big Confidence in This Biotech Stock

TIPRANKS
·
Aug 13

OrbiMed Advisors Acquires $10 Million of BlossomHill Therapeutics Common Shares

Reuters
·
Aug 13

BlossomHill Leaders Go All-In With Bold Insider Buying Spree

TIPRANKS
·
Aug 11

BlossomHill Therapeutics General Counsel Vincent Paul Liptak Buys USD 74,300 of Common Shares

Reuters
·
Aug 11

BlossomHill Therapeutics Adopts Amended, Restated Bylaws Ahead of IPO Close

Reuters
·
Aug 11

BlossomHill Therapeutics Shares Fall in Nasdaq Debut

MT Newswires Live
·
Aug 08